Progress of Drug Use in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Like RNA-Virus Inhibitor

YE Qiaofeng; LU Jinmiao; HUANG Yidie; ZHU Lin; ZHANG Junqi; LI Zhiping

doi:10.14009/j.issn.1672-2124.2020.09.001

您当前的位置：

首页 >

文章列表页 >

Progress of Drug Use in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Like RNA-Virus Inhibitor

更新时间：2022-10-08

- Progress of Drug Use in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Like RNA-Virus Inhibitor
- Vol. 20, Issue 9, Pages: 1025-1029(2020)
- 作者机构：
  
  国家儿童医学中心/复旦大学附属儿科医院临床药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.09.001
  CLC： R978.7
- Published：2020，
扫描看全文
[1]叶乔峰,卢金淼,黄怡蝶,朱琳,张俊琦,李智平.严重急性呼吸综合征冠状病毒2型类似RNA病毒抑制剂的儿童用药研究进展[J].中国医院用药评价与分析,2020,20(09):1025-1029.

YE Qiaofeng, LU Jinmiao, HUANG Yidie, et al. Progress of Drug Use in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Like RNA-Virus Inhibitor. [J]. 20(9):1025-1029(2020)
[1]叶乔峰,卢金淼,黄怡蝶,朱琳,张俊琦,李智平.严重急性呼吸综合征冠状病毒2型类似RNA病毒抑制剂的儿童用药研究进展[J].中国医院用药评价与分析,2020,20(09):1025-1029. DOI： 10.14009/j.issn.1672-2124.2020.09.001.

YE Qiaofeng, LU Jinmiao, HUANG Yidie, et al. Progress of Drug Use in Children with Severe Acute Respiratory Syndrome Coronavirus 2-Like RNA-Virus Inhibitor. [J]. 20(9):1025-1029(2020) DOI： 10.14009/j.issn.1672-2124.2020.09.001.

摘要

在阻断传播途径的前提下

快速识别预防和治疗新型冠状病毒肺炎（COVID-19）的有效药物是当前的主要挑战。目前

在COVID-19的治疗中

抗病毒药的应用主要依据以往对抗类似抗病毒药的临床治疗证据以及最近陆续发表的临床研究结果。核苷类似物法匹拉韦、利巴韦林分别在埃博拉病毒和丙型肝炎病毒感染的儿童群体中有相关的应用经验;蛋白酶抑制剂洛匹那韦和利托那韦是人类免疫缺陷病毒感染患儿的一线治疗药物;干扰素已有在COVID-19患儿中用法、用量的推荐;氯喹和羟氯喹具有抗病毒活性和免疫调节作用

可用于治疗儿童疟疾、肠外阿米巴病、肝脓肿、系统性红斑狼疮和幼年型类风湿关节炎;阿比多尔和奥司他韦可用于儿童流行性感冒的预防和治疗。

Abstract

On top of cutting off the route of transmission

rapid identification of effective drugs for the prevention and treatment of COVID-19 is the current major challenge. At present

in the treatment of COVID-19

the application of antiviral drugs is mainly based on previous clinical treatment evidence against similar antiviral drugs and the results of recent clinical studies. Nucleoside analogues frapiravir and ribavirin have been used in children infected with Ebola virus and hepatitis C virus respectively. Proteinase inhibitors such as lopinavir and ritonavir are the first-line treatment for pediatric HIV infection. Interferon has been recommended for use and dosage in children with COVID-19.Chloroquine and hydroxychloroquine have antiviral activity and immunomodulatory effects

and evidence on the treatment of malaria

extraintestinal amebiasis

liver abscess

systemic lupus erythematosus and juvenile rheumatoid arthritis is available for pediatrics. Abidol and oseltamivir can be used for the prevention and treatment of influenza in children.

关键词

新型冠状病毒肺炎严重急性呼吸综合征冠状病毒2型RNA病毒抑制剂儿童研究进展

Keywords

COVID-19Severe acute respiratory syndrome coronavirus 2RNA-virus inhibitorChildrenProgress

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress of Antiviral Research of Arbidol

Systematic Review on Efficacy and Safety of Compound Glycyrrhizin Injection in Adjuvant Treatment of Children with Henoch-Schonlein Purpura

Information Annotation in Drug Instructions of Topical Drugs in Dermatology of Eight Children’s Hospitals

Correlation Between CHI3L1 Gene Polymorphism and Efficacy of Inhaled Glucocorticoid in Children with Bronchial Asthma

A Rapid Health Technology Assessment of Xiyanping Injection in the Treatment of Respiratory System Diseases in Children

Related Author

BAI Jiawei

MA Chengtai

WEI Jie

WU Miao

DU Xianjin

REN Xiangge

HE Mei

JI Cong

Related Institution

Dept.of Emergency, Renmin Hospital of Wuhan University

Dept.of Critical Care Medicine, Renmin Hospital of Wuhan University

Dept.of Pediatrics, the First Affiliated Hospital of Henan University of Chinese Medicine

College of Pediatrics, Henan University of Chinese Medicine

Dept.of Clinical Pharmacy, Anhui Provincial Children’s Hospital

⁰